Bifunctional and -opioid receptor (OR) ligands are potential therapeutic alternatives, with diminished side effects, to alkaloid opiate analgesics. We solved the structure of human -OR bound to the bifunctional -OR antagonist and -OR agonist tetrapeptide H-Dmt-Tic-Phe-Phe-NH 2 (DIPP-NH 2 ) by serial femtosecond crystallography, revealing a cis-peptide bond between H-Dmt and Tic. The observed receptor-peptide interactions are critical for understanding of the pharmacological profiles of opioid peptides and for development of improved analgesics.
The management of pain, mood states and other neurophysiological processes is regulated by the release of classical endogenous opioid peptides, such as endomorphins, enkephalins and dynorphins, that selectively bind to and activate their respective µ-, δand κ-OR subtypes 1 . Alkaloid opiates such as morphine, targeting µ-OR, are the most widely used analgesics for the treatment of moderate to severe pain, but chronic administration produces side effects such as tolerance, dependence and addiction. Coadministration of the δ-OR antagonist naltrindole has been shown to prevent the development of morphineinduced tolerance and dependence 2 , thus prompting the design of compounds with a mixed δ-OR-antagonist and µ-OR-agonist function. This bifunctional pharmacological profile has been achieved with both morphinan-based small molecules and opioid-peptide analogs, to produce compounds with reduced liability for tolerance and dependence in vivo, thus suggesting their high therapeutic potential 3, 4 .
The bifunctional δ-OR-antagonist and µ-OR-agonist tetrapeptide DIPP-NH 2 (H-Dmt-Tic-Phe-Phe-NH 2 , with Dmt representing 2′,6′-dimethyltyrosine and Tic representing 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) ( Fig. 1) is a member of the so-called H-Tyr-Tic-Phe-Phe-OH (TIPP) class of endomorphin-derived peptide analogs displaying profiles of δ-OR-antagonist activity or mixed δ-OR and µ-OR activity [5] [6] [7] . Subtle changes in their chemical structure were previously found to modulate the functional profiles of these ligands 8, 9 . The most noteworthy modulation was achieved by replacement of a proline (present in endogenous peptides such as endomorphin-2, H-Tyr-Pro-Phe-Phe-NH 2 ) by a Tic scaffold, to result in potent compounds with mixed δ-OR-antagonist and µ-OR-agonist activities 10 , including DIPP-NH 2 (ref. 7) . However, the structural basis leading to these pharmacological profiles is not understood.
To gain structural insights into the binding mode and OR-subtype specificity of DIPP-NH 2 , we engineered and crystallized a receptor construct containing the thermostabilized apocytochrome b 562 RIL (BRIL) fused to the N terminus of human δ-OR (residues 38-336, BRIL∆ 38 δ-OR) in complex with DIPP-NH 2 ( Supplementary Fig. 1 and Online Methods). Radioligand competition data confirmed that the construct used for structure determination binds DIPP-NH 2 with similar affinity as that of the wild-type (WT) receptor ( Supplementary Fig. 2 ). We initially determined the X-ray crystal structure of the BRIL∆ 38 δ-OR-DIPP-NH 2 complex at 3.3-Å resolution, using synchrotron X-ray diffraction of cryocooled crystals. Subsequently, we applied a recently developed serial femtosecond crystallography approach in lipidic cubic phase (LCP) 11, 12 , using an X-ray free electron laser (XFEL), and determined the room-temperature structure of the complex at 2.7-Å resolution b r i e F c o m m u n i c at i o n s ( Fig. 1, Supplementary Figs. 3 and 4 and Supplementary Table 1 ). Despite subtle differences, both BRIL∆ 38 δ-OR-DIPP-NH 2 structures are very similar, with a r.m.s. deviation (r.m.s.d.) of 0.5 Å over all structurally characterized receptor Cα atoms, and therefore we used the higher-resolution XFEL structure in subsequent analysis. Overall, the inactive-state δ-OR-DIPP-NH 2 structure is similar to the previously determined 1.8-Å-resolution structure of δ-OR bound to the morphinan derivative naltrindole 13 (r.m.s.d. of 0.85 Å, excluding five N-terminal and seven C-terminal residues). However, the DIPP-NH 2 binding observed in the δ-OR-DIPP-NH 2 structure is distinct from that of morphinan or peptidomimetic derivatives found in previous OR structures of µ-, κand δ-subtypes [14] [15] [16] , thus revealing new molecular determinants of a peptide interaction with δ-OR ( Fig. 2a,b ). DIPP-NH 2 binding induces an apparent expansion of the δ-OR orthosteric site, resulting primarily from a concomitant outward movement of the extracellular parts of helices II and VI (1.1-Å increase in the distance measured between Cα atoms of Tyr109 2.64 and Trp284 6.58 , with superscript corresponding to the Ballesteros-Weinstein residue numbering), accompanied by an outward movement of ~2 Å of the extracellular loop 2 (ECL2) ( Fig. 2c,d) .
DIPP-NH 2 (molecular weight, 661 g/mol; volume, 674 Å 3 ) fills most of the δ-OR orthosteric binding-site cavity, partially overlapping with the morphinan pharmacophore group of the smaller antagonist naltrindole (molecular weight, 415 g/mol; volume, 456 Å 3 ) ( Figs. 1d and 2d) . The tetrapeptide is oriented so that the Dmt residue reaches deep toward the core of the receptor, while Phe4 is positioned at the extracellular entrance of the orthosteric site, with the Phe4-NH 2 main chain amide interacting with ECL2. Whereas residues H-Dmt, Tic and Phe3 tightly fit into a well-defined cavity and have B factors lower than the average B factor of the protein (<60 Å 2 ), Phe4-NH 2 is less restricted, with B factors exceeding 100 Å 2 . Electron density suggests that this residue potentially adopts a dual conformation in molecule B of the synchrotron structure; however, the moderate resolution of this structure precludes accurate modeling of two conformations, and therefore we used only the strongest one in the refinement. The alternative conformation of Phe4-NH 2 in molecule B of the synchrotron structure is rotated away from ECL2, as compared to the conformation found in molecule A and also to the conformation of molecules A and B observed in the XFEL structure ( Supplementary Fig. 4) .
The Dmt residue of DIPP-NH 2 interacts with Met132 3.36 , Tyr129 3.33 , Val217 5.43 , Val281 6.55 , Ile277 6.51 and Trp284 6.58 , so that the Dmt side chain approximately overlaps with the hydroxyphenyl moieties of morphinan and peptidomimetic ligands [14] [15] [16] (Fig. 2a,b) . As compared to these hydroxyphenyl moieties, which presumably mimic the Tyr1 residue in endogenous opioid peptide ligands, the 2′ and 6′ methyl groups in Dmt of DIPP-NH 2 , when added, result in a better shape complementarity within the hydrophobic cavity, in line with the improved binding affinity and potency of Dmt1-containing opioid peptides 6 . The plane of the Dmt phenol ring deviates approximately 30° from the corresponding hydroxyphenyl groups of δ-OR and µ-OR morphinan antagonists (naltrindole in δ-OR; β-funaltrexamine (β-FNA) in µ-OR) 13, 15 , thus placing one of the two Dmt methyl groups in proximity to Val281 6.55 and Ile277 6.51 , and placing the 6′ methyl against the aromatic side chain of Tyr129 3.33 (Figs. 1a,c,d and 2a,d). As expected, the N-terminal amine of Dmt is coordinated by a salt bridge with the side chain of Asp128 3.32 (Fig. 1c) , an anchor interaction critical for OR ligand recognition [14] [15] [16] .
The amide bond between the first and second residues of DIPP-NH 2 has the cis configuration with the Tic side chain in the gauche + conformation, overlaying with the benzene moiety of the indole ring in naltrindole ( Fig. 2d) 13 . The observed binding pose of DIPP-NH 2 is consistent with NMR spectroscopic data showing that TIPP peptides in solution undergo a slow dynamic exchange between conformations containing cis and trans configurations of the Tyr1-Tic peptide bond 17 . Similarly, a cis configuration of the Tyr1-Pro2 amide bond was also proposed as the bioactive conformation in endomorphin analogs 18 . The Tic side chain occupies a hydrophobic pocket formed by helices VI and VII, adjacent to that occupied by Dmt. This pocket is formed by the side chains of Ile277 6.51 , Ile304 7.39 , Leu300 7.35 , Trp284 6.58 and Val281 6.55 , with the aromatic group of Tic making a π-π interaction with Trp284 6.58 and stacking with the Val281 6.55 side chain (Fig. 1) . The interactions of Tic and the Dmt 2′ methyl group with Val281 6.55 apparently contributes to an ~1.1-Å outward shift of the Val281 6.55 side chain on the extracellular side of helix VI, as compared to the naltrindole-bound δ-OR structure 13 (Fig. 2d) .
The δ-OR-DIPP-NH 2 structure highlights important atomic details for the bifunctional pharmacological profile of DIPP-NH 2 at the µand δ-OR, which is centered prominently around the pocket binding the Tic chemotype. Superposition of the current δ-OR-DIPP-NH 2 structure with the µ-OR inactive-state structure (PDB 4DKL) 15 reveals that the Tic pharmacophore clashes with side chains of nonconserved Trp318 7.35 and Lys303 6.58 in the µ-OR (equivalent to Leu300 7.35 and Trp284 6.58 in δ-OR, respectively) ( Fig. 2a,b) . The δ-OR double mutant, bearing mutations L300 7.35 W and W284 6.58 K, demonstrated a decrease of over two orders of magnitude in the affinity of both H-Tyr-Ala-Gly-Phe-Leu-OH (DADLE) and DIPP-NH 2 peptides (data not shown), thus preventing further characterization of the functional effects of these mutations. Because Tic is critical for the bifunctional profile, this divergent interaction site is likely to have a key role in defining δ-OR-agonist versus δ-OR-antagonist properties of opioid peptide ligands. DIPP-NH 2 had previously been characterized as a δ-OR antagonist and µ-OR agonist in the classical mouse vas deferens and guinea pig ileum functional assays 7 . The present pharmacological data obtained in cell-based assays confirmed that the peptide is a full agonist at the µ-OR, with similar potency and efficacy as those of the endogenous peptides endomorphin-1 and endomorphin-2 in the Gα i -protein pathway, and a partial agonist for β-arrestin recruitment (Supplementary Fig. 5a,b) . Further, the pharmacological characterization revealed that although DIPP-NH 2 shows a weak partial agonist activity for both Gα i -protein and β-arrestin pathways at the human δ-OR ( Supplementary Fig. 5c,d) , Schild analysis confirmed its antagonist activity profile with respect to the prototype peptide agonist DADLE, which is structurally related to the endogenous peptide agonist enkephalin (H-Tyr-Gly-Gly-Phe-Met/Leu-OH) ( Supplementary Fig. 5e,f) .
The δ-OR-DIPP-NH 2 structure also reveals important features of the peptide-recognition site, beyond the naltrindole-defined pocket in previous δ-OR structures 13, 14 . The Phe3 aromatic side chain of DIPP-NH 2 reaches back toward the receptor core and interacts with the hydrophobic side chain of Leu125 3.29 , just below ECL2, as well as with the carbon atoms of Tyr129 3.33 and Asp128 3.32 side chains ( Figs. 1 and 2) . Although the Phe3 side chain is not involved in other hydrophobic interactions, its role in DIPP-NH 2 binding to δ-OR is likely to shield the salt bridge between the N-terminal amine and Asp128 3.32 from solvent, thus stabilizing this ionic interaction. Outside of the pocket concealing H-Dmt-Tic-Phe3, the terminal Phe4-NH 2 group in its major conformation is found forming two hydrogen bonds to the main chain carbonyl and nitrogen atoms of Leu200 ECL2 . The side chain of Phe4 rests against Met199 ECL2 , which together with Val197 ECL2 forms a hydrophobic patch on the δ-OR ECL2 β-sheet. The equivalent positions at µ-OR are occupied by charged or polar residues, thus suggesting that the chemical character of residues on ECL2 may be important for OR peptide selectivity ( Fig. 2a) . Superimposition of µ-OR bound to β-FNA and δ-OR-DIPP-NH 2 structures show a clash between µ-OR Thr218 ECL2 and DIPP-NH 2 , thus rationalizing the shift of ECL2 in the δ-OR-DIPP-NH 2 structure (Fig. 2a,c) .
Currently, understanding of the structural determinants for peptide binding to ORs and GPCRs in general is limited because the only other GPCR structure bound to an endogenous peptide is the structure of neurotensin receptor 1 (ref. 19 ). The δ-OR-DIPP-NH 2 structure presented here offers an opportunity to examine the binding mode of a prototype peptide analog and provides a structural platform for the rationalization of structure-activity relationship studies of numerous other reported peptides with distinct pharmacological properties. Because the structural relationship between equivalent positions of functional groups in small-molecule ligands and peptides is often not easy to define, the δ-OR-DIPP-NH 2 structure should prove useful for further understanding of OR function and selectivity. Furthermore, this structure is of the utmost interest for structurebased drug-design efforts, given the potent mixed δ-OR antagonist and µ-OR agonist activity of DIPP-NH 2 , a profile known to attenuate opioid side effects. Thus, the structure of the δ-OR-DIPP-NH 2 complex provides a structural basis for development of both peptidic and nonpeptidic ligands as drugs for treatment of pain pathologies through opioid-based therapy.
MeTHODs
Methods and any associated references are available in the online version of the paper.
Accession codes.
Coordinates and structure factors have been deposited in the Protein Data Bank under accession codes 4RWA (synchrotron structure) and 4RWD (XFEL structure). with biophysical characterization of crystals at LCLS; D.T. and P.W.S. helped with manuscript preparation; B.L.R. supervised the pharmacology studies, analyzed the data and wrote the paper; S. Ballet supervised the peptide synthesis and screening studies, synthesized peptide ligands for structural studies and wrote the paper; V.K. analyzed the data and wrote the paper; R.C.S. determined the overall project strategy, analyzed the data and wrote the paper; V.C. determined the overall project strategy and provided management, supervised XFEL data collection, analyzed the data and wrote the paper with contributions from all other coauthors. 4.6 h and yielded 36,083 indexed patterns. Data-resolution cutoff was selected on the basis of the behavior of the Pearson correlation coefficient (CC 1/2 = 0.538 in the highest-resolution shell).
XFEL structure determination and refinement. The XFEL structure was determined with the same procedure used to determine the synchrotron structure described above. The final model contains 98.5% residues in favored and 1.5% in allowed Ramachandran-plot regions. The data collection and refinement statistics are shown in Supplementary Table 1 .
-OR -arrestin-recruitment Tango assay. Arrestin recruitment assays were performed as previously described 13 with a modified version of the original Tango assay 31 .
-OR -arrestin-recruitment bioluminescence resonance energy transfer assay. µ-OR β-arrestin-translocation assay was performed with a bioluminescence resonance energy transfer (BRET)-based assay as originally described 32 . In brief, HEK293T cells (ATCC CRL-11268) were cotransfected with cDNA encoding the µ-OR fused at the C terminus with the Renillla reniformis luciferase (Luc8) and with the Venus-tagged β-arrestin-2 and G protein-coupled receptor kinase 2. 24 h post-transfection, cells were distributed on clear-bottom white poly-llysine-coated 96-well plates. The next day, cells were rinsed once with PBS and incubated 10 min in 90 µl of assay buffer (1 × HBSS and 20 mM HEPES, pH 7.40) containing 5 µM coelenterazine-h. Then cells were stimulated for 15 min by the addition of 10 µl of 10× drugs diluted in assay buffer, and emitted light was collected with a Mithras LB-940 reader (Berthold Technologies). cAMP assays. cAMP was quantified with a luciferase-based Glosensor bioassay (Promega) as previously described 13 in transiently transfected HEK293T cells. Data were normalized compared to the agonist DAMGO for the µ-OR and DADLE for the δ-OR, and a nonlinear regression was applied with the sigmoidal dose-response function.
DIPP-NH 2 binding assays. Binding of DIPP-NH 2 to δ-OR and µ-OR was performed as previously described 13 .
Statistical analysis. Data for ligand binding and signaling assays are presented as mean ± s.e.m. from three independent experiments (n = 3) conducted in quadruplicate. Data were analyzed with GraphPad Prism.
